

**ASX Announcement**  
**7 October 2024 (Melbourne, Australia)**  
**Optiscan Imaging Ltd (ASX:OIL)**

**Annual General Meeting Date**

**Optiscan Imaging Limited (ASX:OIL)** ('Optiscan' or 'the Company') advises that in accordance with ASX Listing Rule 3.13.1 its Annual General Meeting ('AGM') will be held on Thursday, 21 November 2024. Accordingly, for the purposes of ASX Listing Rule 3.13.1 the Company advises that the closing date for nominations for the position of Director is 5:00pm (AEDT) on 14 October 2024.

The Company notes that the deadline for nominations for the position of Director is separate to voting on the election of Director. Details of the Directors nominated to be elected will be provided in the Company's Notice of AGM in due course.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

**For further information, please contact:**

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

**T:** +61 3 9538 3333

**E:** [ceo@optiscan.com](mailto:ceo@optiscan.com)

Media & Investor Enquiries

The Capital Network

Julia Maguire

**T:** +61 2 7257 7338

**E:** [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

**About Optiscan**

Optiscan Imaging Ltd (ASX:OIL) is a commercial stage medical technology company creating a suite of digital pathology and precision surgery hardware and software solutions that enable live optical biopsy for life sciences, diagnostic and surgical applications. Optiscan pioneered the development and manufacturing of miniaturised digital endomicroscopes with spatial resolution more than 1000x that of medical CT and MRI.

Using a revolutionary "tissue contact" method, Optiscan's patented technology produces super high resolution digital pathology images for cancer diagnosis and surgical treatment, to unlock real-time insights during surgery, diagnostics, and pre-clinical research. By enabling live, non-destructive, 3D, in-vivo digital imaging at the single-cell level, Optiscan's technology supports earlier disease detection, precision treatment, and improved patient outcomes across a wide selection of clinical applications and settings.

The global addressable market for Optiscan's medical imaging technology extends beyond traditional surgery and pathology, to also encompass the fast-growing digital health market including robotic surgery. With an expanding product suite and increased demand for digital health solutions, Optiscan is uniquely positioned to bridge the gap between surgery and pathology and deliver better outcomes for healthcare professionals and their patients.

To learn more about Optiscan, visit [www.optiscan.com](http://www.optiscan.com) or follow us on [LinkedIn](#), [X](#) or [Instagram](#).